Clinical Trials
25 trialsA Phase Ib/II Study of HDM2017 in Combination With Standard of Care in Advanced Colorectal Cancer
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
TriComB
Gruppo Oncologico del Nord-Ovest
CAIRO7
UMC Utrecht
BM7PE
Oslo University Hospital
cruciall
Second Affiliated Hospital, School of Medicine, Zhejiang University
Assessing How Normal Variations in CT Scanning Affects Its Interpretation
Memorial Sloan Kettering Cancer Center
Using Healthy Gut Bacteria to Boost Immune Treatment for Advanced Bowel Cancer
The First Affiliated Hospital of Xiamen University
INFINITIVE: ImmuNotherapy For PatIeNts wIth colorecTal LIVer MEtastases
Northwell Health
Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis
Northwell Health
NEW-COMET
Oslo University Hospital
MARGIN
Centre Hospitalier Universitaire de NÄ«mes
A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer
Carina Biotech Limited
HAITI
Gruppo Oncologico del Nord-Ovest
Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab
Second Affiliated Hospital, School of Medicine, Zhejiang University
CORESIM
Federation Francophone de Cancerologie Digestive
Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Shanghai Kechow Pharma, Inc.
LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615)
The Netherlands Cancer Institute
Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer
Sun Yat-sen University
AUDREY
Enterome
RePERSO
Rennes University Hospital
An Explorative Study of HRS-2189 Combined With Adebrelimab and BP102 for Metastatic Colorectal Cancer
Fudan University
Living Donor Liver Transplant for Unresectable Colorectal Liver Metastases
University of Rochester
Clinical Study of Irinotecan Liposome (II)-Based Combination Treatment for Irinotecan-resistant Colorectal Cancer.
Chinese PLA General Hospital
ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC
Sun Yat-sen University
Efficacy and Safety of DEB-TACE Combined With HAIC Versus HAIC Alone in Patients With Unresectable CRLM
Peking University Cancer Hospital & Institute